Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1

Conditions

Lymphoma, Follicular 1Lupus Erythematosus, Systemic 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 511Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
gusacitinib × Lymphoid × Clear all
NCT06238531 2025-03-13

A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
Lymphoid

Lupus Erythematosus, Systemic, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡